Seek Returns

BIO.B vs. ILMN: Bio-Rad Laboratories vs. Illumina Stock Comparison

How do Bio-Rad Laboratories (BIO.B) and Illumina (ILMN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bio-Rad Laboratories (BIO.B) and Illumina (ILMN) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Company profile comparison for Bio-Rad Laboratories (BIO.B) and Illumina (ILMN)
Profile ItemBIO.BILMN
NameBio-Rad Laboratories, Inc. Class B Common StockIllumina Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
GICS Sub-IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
Market Capitalization10.49 billion USD31.30 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateSeptember 21, 1999July 28, 2000
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BIO.B
ILMN
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Illumina (ILMN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Bio-Rad Laboratories (BIO.B) and Illumina (ILMN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Bio-Rad Laboratories (BIO.B) and Illumina (ILMN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bio-Rad Laboratories (BIO.B) and Illumina (ILMN)
MetricBIO.BILMN
Total Return (1Y)27.69%72.61%
Total Return (3Y, Annualized)9.13%31.87%
Total Return (5Y, Annualized)-12.33%-11.11%

Risk Profile

Drawdown History

BIO.B
ILMN
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Illumina (ILMN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Bio-Rad Laboratories (BIO.B) and Illumina (ILMN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Illumina (ILMN) trades around 2.79M shares per day on average, while Bio-Rad Laboratories (BIO.B) sees only 11 — a volume gap that can matter for position sizing, exit liquidity, and order execution.

Risk profile metrics for Bio-Rad Laboratories (BIO.B) and Illumina (ILMN)
MetricBIO.BILMN
Volatility (1Y, Annualized)30.96%48.53%
Beta (5Y)1.001.47
Max Drawdown (5Y)-70.74%-82.95%
Avg. Volume (3M)112.79M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BIO.B and ILMN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bio-Rad Laboratories (BIO.B) and Illumina (ILMN)
MetricBIO.BILMN
Sharpe Ratio (1Y)0.741.40
Sortino Ratio (1Y)1.102.02

Profitability

ROE (TTM)

Both Bio-Rad Laboratories (BIO.B) at 14.27% and Illumina (ILMN) at 32.39% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max
109.18%
BIO.B
14.27%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.39%

Max
109.18%
ILMN
32.39%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Illumina (ILMN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Bio-Rad Laboratories (BIO.B) at 39.45% and Illumina (ILMN) at 19.72% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO.B
39.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.72%

ILMN
19.72%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Illumina (ILMN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Illumina (ILMN) at 19.06% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO.B) at 9.46%, which runs around its industry’s norm.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.46%

Max
83.12%
Q3
14.77%
BIO.B
9.46%
Median
0.00%
Q1
-78.82%
Min
-207.40%

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.06%

Max
83.12%
ILMN
19.06%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Illumina (ILMN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bio-Rad Laboratories (BIO.B) and Illumina (ILMN)
MetricBIO.BILMN
ROE (TTM)14.27%32.39%
ROA (TTM)1.50%8.32%
Net Margin (TTM)39.45%19.72%
Operating Margin (TTM)9.46%19.06%
Gross Margin (TTM)52.19%67.68%

Growth

Revenue Growth

Bio-Rad Laboratories (BIO.B) at 0.65% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Illumina (ILMN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Bio-Rad Laboratories (BIO.B) nor Illumina (ILMN) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Bio-Rad Laboratories (BIO.B) and Illumina (ILMN)
MetricBIO.BILMN
Revenue Growth (YoY)0.65%-0.66%
Revenue Growth (3Y CAGR)-2.68%-1.78%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Both Bio-Rad Laboratories (BIO.B) at 3.18 and Illumina (ILMN) at 2.63 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max
25.13
Q3
12.13
Median
5.52
BIO.B
3.18
Q1
2.47
Min
0.10

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max
25.13
Q3
12.13
Median
5.52
ILMN
2.63
Q1
2.47
Min
0.10
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Illumina (ILMN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Bio-Rad Laboratories (BIO.B) at 0.18 carries an industry-typical debt-to-equity mix, while Illumina (ILMN) at 0.74 uses more debt funding than most peers.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max
1.42
Q3
0.65
BIO.B
0.18
Median
0.15
Q1
0.02
Min
0.00

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.74

Max
1.42
ILMN
0.74
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Illumina (ILMN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Bio-Rad Laboratories (BIO.B) and Illumina (ILMN)
MetricBIO.BILMN
Current Ratio (MRQ)3.182.63
Debt / Equity (MRQ)0.180.74
Net Debt / EBITDA-0.730.85

Dividends

Dividend Yield (TTM)

Neither Bio-Rad Laboratories (BIO.B) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Illumina (ILMN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Bio-Rad Laboratories (BIO.B) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Illumina (ILMN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bio-Rad Laboratories (BIO.B) and Illumina (ILMN)
MetricBIO.BILMN
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Bio-Rad Laboratories (BIO.B) at 10.36 sits in the cheaper P/E ratio quartile, while Illumina (ILMN) at 35.63 is closer to its industry’s usual earnings multiple — a discount for BIO.B, though growth and earnings durability still matter.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.36

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
BIO.B
10.36
Min
0.07

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.63

Max
85.34
Q3
43.46
ILMN
35.63
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Illumina (ILMN): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Bio-Rad Laboratories (BIO.B) at 4.05 and Illumina (ILMN) at 6.90 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.05

Max
58.18
Q3
25.77
Median
7.30
BIO.B
4.05
Q1
3.01
Min
0.01

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.90

Max
58.18
Q3
25.77
Median
7.30
ILMN
6.90
Q1
3.01
Min
0.01
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Illumina (ILMN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 1.38 looks cheap against book in the lower P/B ratio quartile, while Illumina (ILMN) at 10.00 carries a premium in the upper quartile — a clear price-to-book gap.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BIO.B
1.38
Min
-5.59

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.00

Max
13.53
ILMN
10.00
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Illumina (ILMN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bio-Rad Laboratories (BIO.B) and Illumina (ILMN)
MetricBIO.BILMN
P/E Ratio (TTM)10.3635.63
P/S Ratio (TTM)4.056.90
P/B Ratio (MRQ)1.3810.00
Free Cash Flow Yield (TTM)2.59%2.74%